INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

Review Paper

Artificial Intelligence in Oral Solid Dosage Form Development and Optimization

Priti Shinde*, S. Ambore

D K Patil institute of Pharmacy Loha.

ARTICLE INFO

Published: 06 July 2026
Keywords:
Artificial Intelligence, Oral Solid Dosage Forms, Machine Learning, Formulation Optimization, Process Analytical Technology.
DOI:
10.5281/zenodo.21217922

ABSTRACT

Artificial Intelligence (AI) has emerged as a transformative technology in the pharmaceutical industry, shifting oral solid dosage form (OSDF) development from conventional trial-and-error methods to efficient, data-driven strategies. The design of OSDFs involves a complex interplay of multiple variables, such as physicochemical properties, excipient selection, manufacturing parameters, and stability considerations. The integration of AI—primarily driven by machine learning (ML) and deep learning (DL) architectures—enables researchers to rapidly analyze large, multi-dimensional datasets to establish accurate predictive insights throughout the product lifecycle. This review highlights the diverse applications of AI across multiple stages of OSDF development. In pre-formulation and formulation design, AI algorithms predict drug-excipient compatibility, optimize composition, and forecast critical quality attributes (CQAs) like tablet hardness, dissolution kinetics, and shelf life. Furthermore, AI technologies revolutionize manufacturing and process control within the industry 4.0 framework. By integrating Process Analytical Technology (PAT) and computer vision, AI facilitates real-time monitoring and parameter optimization during critical unit operations, including granulation, compression, and coating, thereby dramatically reducing batch defects and material waste. AI also significantly enhances Quality by Design (QbD) implementation by defining robust design spaces. Despite persisting challenges regarding high-quality data availability, model interpretability ("black-box" models), implementation costs, and evolving regulatory frameworks, the future of AI in pharmaceuticals remains highly promising. Emerging paradigms like digital twins, autonomous self-driving laboratories, and personalized medicine are set to further modernize OSDF manufacturing, ensuring the rapid, cost-effective production of safe and high-quality therapeutics.

***Corresponding Author:** Priti Shinde
Address: *Guru Nanak Institute of Pharmaceutical Science & Technology 157/F Nilgunj Road, Sodepur, Kolkata- 700114.*
Email ✉: shindepriti993@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

INTRODUCTION

Artificial Intelligence (AI) has emerged as a transformative technology in the pharmaceutical industry, offering innovative solutions to complex challenges encountered during drug development and manufacturing. Traditional pharmaceutical development relies heavily on trial-and-error approaches, which are often time-consuming, labor-intensive, and costly. The integration of AI technologies enables researchers to analyze large datasets, identify hidden patterns, predict outcomes, and optimize formulations with greater precision and efficiency (1,2).

The pharmaceutical sector generates vast amounts of data from formulation studies, process development, quality control testing, and clinical investigations. AI tools can process these datasets rapidly and provide predictive insights that support decision-making throughout the product lifecycle. In recent years, AI has been increasingly utilized in drug discovery, formulation optimization, process analytical technology (PAT), quality-by-design (QbD), and personalized medicine (3,4).

Oral solid dosage forms (OSDFs), including tablets, capsules, powders, and granules, represent the most widely used pharmaceutical dosage forms due to their convenience, stability, and patient compliance. However, the development of OSDFs involves multiple variables such as drug physicochemical properties, excipient selection, manufacturing parameters, dissolution characteristics, and stability considerations. AI-based approaches can significantly improve formulation development by predicting critical quality attributes (CQAs), optimizing process parameters, and reducing experimental workload (5,6).

The growing adoption of machine learning, deep learning, and data analytics in pharmaceutical sciences has accelerated the transition toward data-driven formulation development. Consequently, AI is becoming an essential tool for enhancing efficiency, reducing costs, improving product quality, and facilitating regulatory compliance in oral solid dosage form development (7,8).

Role of AI in Pharmaceutical Development

Big Data
↓
Artificial Intelligence
↓
Machine Learning
↓
Predictive Modeling
↓
Formulation Optimization
↓
Quality Enhancement & Cost Reduction

2. Overview of Artificial Intelligence in Pharmaceuticals

Artificial Intelligence refers to the ability of computer systems to perform tasks that normally require human intelligence, including learning, reasoning, decision-making, pattern recognition, and problem-solving. AI systems utilize mathematical algorithms and computational models to analyze large datasets and generate meaningful predictions (1).

In pharmaceutical sciences, AI has become a powerful tool for accelerating research and development activities. Applications include drug discovery, target identification, molecular modeling, formulation development, process optimization, quality assurance, and regulatory decision support. AI enables researchers to predict formulation performance, optimize manufacturing processes, and identify critical variables affecting product quality (2,3).

The implementation of AI in pharmaceutical manufacturing aligns with the principles of Industry 4.0, where automation, data analytics, and intelligent systems are integrated to improve

productivity and process control. Regulatory agencies such as the United States Food and Drug Administration (FDA) have recognized the potential of AI and machine learning technologies in enhancing pharmaceutical innovation and quality management systems (4,5).

Table 1. Applications of AI in Pharmaceutical Sciences

Area	AI Application
Drug Discovery	Lead identification and optimization
Preformulation	Solubility and stability prediction
Formulation Development	Excipient selection and optimization
Manufacturing	Process monitoring and control
Quality Control	Defect detection and dissolution prediction
Regulatory Affairs	Risk assessment and compliance support
Personalized Medicine	Patient-specific dosage prediction

3. Artificial Intelligence

Artificial Intelligence is a broad field of computer science focused on creating systems capable of mimicking human cognitive functions. AI systems can learn from data, recognize patterns, solve problems, and make decisions with minimal human intervention. Modern AI technologies are primarily driven by advances in computational power, cloud computing, and the availability of large datasets (1,2).

AI techniques commonly used in pharmaceutical research include expert systems, fuzzy logic, genetic algorithms, machine learning, and deep learning. These approaches facilitate the prediction of formulation behavior, optimization of manufacturing conditions, and assessment of product quality attributes (3).

In oral solid dosage form development, AI assists in identifying optimal formulation compositions, predicting dissolution profiles, estimating stability, and minimizing batch failures. AI-driven models can evaluate thousands of formulation variables simultaneously, enabling more efficient and cost-effective product development (6,7).

Hierarchy of Artificial Intelligence

A

rtificial Intelligence (AI)





Figure 1: The Technical Hierarchy of AI in Formulation Design

4. Machine Learning

Machine Learning (ML) is a subset of AI that enables computer systems to learn from historical data without explicit programming. ML algorithms identify relationships between input variables and outcomes, allowing the prediction of future events or behaviors (2,4).

In pharmaceutical formulation development, ML models are widely used for:

- Excipient selection
- Prediction of tablet hardness
- Dissolution profile modeling
- Stability prediction
- Process optimization
- Identification of critical process parameters

Machine learning algorithms improve formulation efficiency by reducing the number of experimental trials required during product development (5,7).

Types of Machine Learning

1. Supervised Learning

Uses labeled datasets to predict known outcomes.

Examples:

- Artificial Neural Networks (ANN)
- Support Vector Machines (SVM)
- Random Forest (RF)

2. Unsupervised Learning

Identifies hidden patterns in unlabeled datasets.

Examples:

- Clustering
- Principal Component Analysis (PCA)

3. Reinforcement Learning

Learns through rewards and penalties to optimize decisions.

Table 2. Common Machine Learning Algorithms in Pharmaceutical Development

Algorithm	Application
ANN	Dissolution and formulation prediction
Random Forest	Variable importance analysis
SVM	Classification and quality prediction
Decision Tree	Risk assessment
K-Means Clustering	Data segmentation
PCA	Multivariate data analysis

Machine Learning Workflow

Data Collection
↓
Data Preprocessing
↓
Feature Selection
↓
Model Training
↓
Validation

↓
Prediction
↓
Decision Making

5. Deep Learning

Deep Learning (DL) is an advanced subset of machine learning that utilizes multilayered artificial neural networks to process complex datasets and identify intricate patterns. Unlike traditional ML techniques, deep learning can automatically extract features from large datasets without extensive manual intervention (8,9).

Deep learning models have demonstrated significant success in pharmaceutical applications, including molecular property prediction, image analysis, process monitoring, and formulation optimization. The ability of deep neural networks to handle nonlinear relationships makes them particularly useful for oral solid dosage form development, where multiple formulation and process variables interact simultaneously (9,10).

Common deep learning architectures include:

- Deep Neural Networks (DNN)
- Convolutional Neural Networks (CNN)
- Recurrent Neural Networks (RNN)
- Autoencoders

In OSDF development, deep learning can predict dissolution behavior, classify tablet defects, estimate stability, and optimize manufacturing parameters with high accuracy (10,11).



Figure 2: End-to-End Machine Learning Workflow for OSDFs

Table 3. Comparison of AI, ML, and DL

Feature	AI	ML	DL
Scope	Broad concept	Subset of AI	Subset of ML
Data Requirement	Moderate	High	Very High
Feature Engineering	Manual	Semi-automatic	Automatic
Computational Cost	Moderate	High	Very High
Prediction Accuracy	Moderate	High	Very High
Pharmaceutical Applications	General decision support	Formulation optimization	Complex predictive modeling

5. Oral Solid Dosage Forms: An Overview

Oral solid dosage forms (OSDFs) are among the most widely used pharmaceutical dosage forms due to their convenience, patient compliance, stability, ease of administration, accurate dosing, and cost-effective manufacturing. OSDFs include

tablets, capsules, powders, granules, pellets, and modified-release systems. These dosage forms account for a major proportion of commercially available pharmaceutical products worldwide (12).

The development of oral solid dosage forms involves several critical stages, including preformulation studies, formulation development, process optimization, scale-up, and quality control. Various factors such as drug solubility, particle size, compressibility, flow properties, and compatibility with excipients significantly influence the quality and performance of the final product (13).

Recent advances in pharmaceutical technology have enabled the integration of computational tools and artificial intelligence into OSDF development. AI-based approaches facilitate the prediction of critical quality attributes (CQAs), optimization of manufacturing processes, and reduction in experimental workload, thereby accelerating product development timelines (14).

Table 4:Classification of Oral Solid Dosage Forms

Dosage Form	Characteristics	Examples
Tablets	Compressed solid unit doses	Paracetamol tablets
Capsules	Drug enclosed in gelatin shell	Amoxicillin capsules
Powders	Finely divided drug particles	Oral rehydration powder
Granules	Agglomerated powder particles	Effervescent granules
Pellets	Spherical multiparticulates	Omeprazole pellets
Modified-release Systems	Controlled drug release	Sustained-release tablets

6. Applications of AI in Oral Solid Dosage Form Development

Artificial intelligence has emerged as a powerful tool in oral solid dosage form development by enabling data-driven decision-making, predictive modeling, and process optimization. AI techniques such as machine learning (ML), deep learning (DL), and artificial neural networks (ANNs) can analyze complex datasets and establish relationships between formulation variables and product performance characteristics (15).

The integration of AI into pharmaceutical formulation development has significantly reduced development time, minimized experimental costs, and improved product quality. AI applications span multiple stages of OSDF development, including preformulation studies, formulation optimization, excipient selection, dissolution prediction, and stability assessment (16).

6.1 Preformulation Studies

Preformulation studies provide essential information regarding the physicochemical and biopharmaceutical properties of drug substances before formulation development. Parameters such as solubility, permeability, polymorphism, pKa, hygroscopicity, and particle size distribution are evaluated during this stage (17).

AI and machine learning algorithms can predict physicochemical properties using molecular descriptors and historical datasets. Predictive models assist researchers in identifying potential formulation challenges at an early stage, thereby reducing experimental requirements and accelerating drug product development (18).

Applications of AI in Preformulation

- Solubility prediction
- Permeability estimation
- Crystal form identification
- Drug-excipient compatibility prediction

- Biopharmaceutical classification prediction

Table 5:AI Applications in Preformulation Studies

Preformulation Parameter	AI Application
Solubility	Prediction of aqueous solubility
Permeability	Estimation of intestinal absorption
Polymorphism	Crystal form classification
Stability	Early degradation prediction
Compatibility	Drug–excipient interaction prediction

6.2 Formulation Design and Optimization

Formulation optimization traditionally involves multiple trial-and-error experiments to identify optimal combinations of excipients and process variables. AI-based approaches enable rapid screening of formulation variables and prediction of formulation performance with reduced experimentation (19).

Machine learning models establish relationships between formulation inputs and outputs such as hardness, friability, disintegration time, dissolution rate, and drug release kinetics. These models facilitate optimization of formulation compositions while maintaining desired product quality attributes (20).

AI-assisted optimization offers several advantages:

- Reduced number of experimental batches
- Faster product development
- Improved formulation robustness
- Enhanced process understanding
- Cost-effective development

AI-Assisted Formulation Optimization

Formulation Variables
(Drug + Excipients)
↓
AI Model
↓
Prediction of CQAs
↓
Optimization
↓
Final Formulation

6.3 Excipient Selection

Excipients play a crucial role in determining the manufacturability, stability, and performance of oral solid dosage forms. Selecting suitable excipients is often challenging because of the large number of available materials and their potential interactions with active pharmaceutical ingredients (APIs) (21).

Artificial intelligence can analyze large formulation databases and identify excipients that are most likely to provide desired product characteristics. Machine learning algorithms evaluate the influence of excipient properties on tablet hardness, dissolution rate, flowability, and stability (22).

AI-assisted excipient selection helps:

- Predict excipient compatibility
- Reduce formulation failures
- Improve tablet quality
- Enhance manufacturing efficiency
- Support Quality-by-Design approaches

Table 6: AI-Based Excipient Selection Parameters

Excipient Property	Impact on Formulation
Particle Size	Flowability and compressibility
Moisture Content	Stability
Solubility	Drug release profile
Density	Blend uniformity
Compressibility	Tablet hardness

6.4 Dissolution and Stability Prediction

Dissolution and stability are critical quality attributes of oral solid dosage forms because they directly affect therapeutic efficacy and shelf life. Conventional dissolution and stability studies require extensive experimentation and long-term storage studies (23).

Artificial intelligence models can predict dissolution profiles and degradation behavior using formulation composition, manufacturing variables, and environmental conditions as inputs. Neural networks and deep learning models have demonstrated high accuracy in predicting dissolution kinetics and stability outcomes (24).

AI-based stability prediction can estimate:

- Shelf life
- Degradation pathways
- Moisture sensitivity
- Temperature effects
- Packaging requirements

Similarly, dissolution prediction models assist in developing formulations with desired release characteristics while minimizing laboratory testing requirements (25).

AI-Based Dissolution Prediction Workflow

Formulation Data
+
Process Parameters
↓
Machine Learning Model
↓
Predicted Dissolution Profile
↓
Optimization of Drug Release

Table 7. Benefits of AI in Dissolution and Stability Studies

Parameter	Conventional Method	AI-Based Method
Time Requirement	High	Low
Experimental Batches	Numerous	Reduced
Cost	High	Lower
Prediction Capability	Limited	High
Decision Making	Manual	Data-driven

7. AI in Manufacturing and Process Optimization

The integration of Artificial Intelligence (AI) into pharmaceutical manufacturing has revolutionized process development by enabling real-time monitoring, predictive analytics, and automated decision-making. Manufacturing processes for oral solid dosage forms involve multiple critical steps, including granulation, compression, and coating, where small variations can significantly affect product quality. AI algorithms can analyze large volumes of process data to identify patterns, optimize operating conditions, and predict product performance, thereby improving efficiency and reducing manufacturing failures (26).

AI-driven manufacturing supports the principles of Industry 4.0 by integrating advanced sensors, machine learning models, and Process Analytical Technology (PAT) tools to achieve continuous process improvement and enhanced product quality. These technologies facilitate proactive control strategies, minimize process variability, and ensure consistent production outcomes (27).

7.1 Granulation

Granulation is a critical manufacturing process used to improve powder flowability, compressibility, and content uniformity before tablet compression. Factors such as binder concentration, impeller speed, granulation time, and moisture content influence granule properties and final product quality (28).

AI and machine learning models can analyze historical process data and establish relationships between process parameters and granule characteristics. Predictive models enable manufacturers to optimize granulation conditions and reduce batch failures. Real-time monitoring systems combined with AI can identify process deviations and recommend corrective actions during manufacturing (29).

Applications of AI in Granulation

- Optimization of granulation time
- Moisture content prediction
- Granule size distribution prediction
- Endpoint determination
- Process fault detection

Table 8: AI Applications in Granulation

Process Parameter	AI Application
Binder Concentration	Granule quality prediction
Impeller Speed	Optimization of granule size
Moisture Content	Endpoint determination
Granulation Time	Process optimization
Temperature	Process monitoring

AI-Assisted Granulation Process

Raw Materials
↓
Granulation Process
↓
Sensor Data Collection
↓
Machine Learning Model
↓
Prediction & Optimization
↓
Optimized Granules

7.2 Compression

Tablet compression is one of the most important stages in oral solid dosage form manufacturing. Compression force, turret speed, dwell time, and tooling characteristics directly affect tablet hardness, friability, thickness, and disintegration properties (30).

AI systems can continuously monitor compression parameters and predict tablet quality attributes in real time. Machine learning models help identify optimal compression conditions, reduce tablet defects, and improve batch consistency. Advanced predictive algorithms can detect issues such as capping, lamination, sticking, and weight variation before they become significant quality concerns (31).

Benefits of AI in Compression

- Real-time process control
- Reduction in tablet defects
- Improved batch consistency
- Enhanced productivity
- Reduced material wastage

Table 9: AI Applications in Tablet Compression

Compression Variable	Quality Attribute Predicted
Compression Force	Tablet hardness
Turret Speed	Weight variation
Dwell Time	Tablet strength
Punch Design	Tablet appearance
Die Fill Depth	Content uniformity

7.3 Coating

Coating is employed to enhance tablet appearance, improve stability, mask unpleasant taste, and achieve modified drug release. Critical coating parameters include spray rate, atomization pressure, inlet air temperature, and coating pan speed (32).

Artificial intelligence facilitates precise control of coating operations by analyzing process data and predicting coating uniformity, film thickness, and coating defects. AI-driven image analysis systems can detect coating imperfections in real time, enabling rapid corrective actions and minimizing product rejection (33).

Applications of AI in Coating

- Film thickness prediction
- Coating uniformity assessment
- Defect detection
- Process parameter optimization
- Spray pattern analysis

AI-Based Coating Process Control

Coating Parameters
(Spray Rate, Temperature)
↓
Sensor Inputs
↓
AI Algorithm
↓
Prediction of Film Quality
↓
Process Adjustment
↓
Uniform Tablet Coating

Table 10:AI Applications in Coating Technology

Coating Parameter	AI Function
Spray Rate	Uniformity prediction
Air Temperature	Process optimization
Pan Speed	Film quality assessment
Atomization Pressure	Defect prevention
Coating Time	Thickness prediction



Figure 3: AI and PAT Integration in Unit Operations (Industry 4.0 Framework)

8. AI in Quality by Design (QbD) and Quality Control

Quality by Design (QbD) is a systematic, science-based approach to pharmaceutical development that emphasizes understanding processes and controlling variability to ensure predefined product quality. AI technologies have significantly enhanced QbD implementation by enabling advanced data analysis, risk assessment, and predictive modeling throughout the product lifecycle (34).

AI tools can evaluate complex interactions between Critical Material Attributes (CMAs), Critical Process Parameters (CPPs), and Critical Quality Attributes (CQAs). Machine learning algorithms assist in defining design spaces, optimizing formulation variables, and identifying factors that have the greatest impact on product quality (35).

AI Applications in QbD

- Risk assessment and ranking
- Design space development
- Identification of CMAs and CPPs
- Process optimization
- Predictive quality modeling

AI-Integrated Quality by Design Framework

Quality Target Product Profile
↓
Identification of CMAs & CPPs
↓
Data Collection
↓
Machine Learning Analysis
↓
Design Space Development
↓
Process Optimization
↓
Quality Assurance

AI in Quality Control

Quality control ensures that pharmaceutical products consistently meet predefined specifications and regulatory requirements. Conventional quality control methods often involve extensive laboratory testing and manual inspection procedures. AI technologies enable automated quality assessment through predictive analytics, image processing, and real-time monitoring systems (36).

Machine learning models can predict dissolution behavior, assay values, content uniformity, and stability outcomes using manufacturing and formulation data. Computer vision systems powered by deep learning are increasingly used to detect tablet defects such as cracks, chips, discoloration, and coating irregularities (37).

Benefits of AI in Quality Control

- Real-time quality monitoring

- Automated defect detection
- Reduced human error
- Improved regulatory compliance
- Faster batch release

9. Machine Learning Models Used in Pharmaceutical Development

Machine learning (ML) has become an essential component of modern pharmaceutical research and development. ML algorithms can analyze complex and high-dimensional datasets to identify relationships between formulation variables, manufacturing parameters, and product quality attributes. These predictive capabilities facilitate data-driven decision-making, reduce experimental workload, and accelerate pharmaceutical product development (38).

Various machine learning models have been successfully applied in drug discovery, preformulation studies, formulation optimization, process control, quality assurance, and regulatory decision-making. The selection of an appropriate ML algorithm depends on the nature of the dataset, prediction objectives, and computational requirements (39).

9.1 Artificial Neural Networks (ANN)

Artificial Neural Networks are computational models inspired by the structure and functioning of the human brain. ANNs consist of interconnected neurons arranged in input, hidden, and output layers. These models are highly effective in handling nonlinear relationships commonly encountered in pharmaceutical formulations (40).

Applications of ANNs include:

- Dissolution profile prediction
- Tablet hardness prediction
- Stability assessment
- Drug release modeling
- Process parameter optimization

ANNs have demonstrated superior predictive performance compared with traditional statistical methods for many pharmaceutical applications (40).

9.2 Random Forest (RF)

Random Forest is an ensemble learning method that combines multiple decision trees to improve prediction accuracy and reduce overfitting. The algorithm is particularly useful for identifying critical formulation and process variables affecting product quality (41).

Applications include:

- Excipient selection
- Stability prediction
- Risk assessment
- Process optimization
- Classification of pharmaceutical datasets

Random Forest models provide excellent interpretability and variable importance ranking, making them valuable tools for Quality by Design (QbD) implementation (41).

9.3 Support Vector Machine (SVM)

Support Vector Machine is a supervised learning algorithm widely used for classification and regression tasks. SVM can efficiently analyze complex pharmaceutical datasets and establish predictive relationships between formulation variables and quality outcomes (42).

Applications include:

- Solubility prediction
- Drug-excipient compatibility assessment
- Dissolution classification
- Quality control analysis
- Process monitoring

SVM models are particularly effective when dealing with small datasets and nonlinear relationships (42).

9.4 Decision Trees

Decision trees are hierarchical models that classify data based on a sequence of decision rules. These models are easy to interpret and provide visual representations of decision-making pathways (43).

Applications include:

- Risk analysis
- Process troubleshooting
- Defect classification
- Quality assessment
- Batch release decision support

Decision trees are frequently used in pharmaceutical manufacturing because of their simplicity and transparency (43).

9.5 Deep Neural Networks (DNN)

Deep Neural Networks are advanced machine learning models consisting of multiple hidden layers that can automatically learn complex features from large datasets. DNNs have significantly improved predictive accuracy in pharmaceutical applications involving nonlinear and multidimensional data (44).

Applications include:

- Drug release prediction
- Stability modeling
- Image-based quality control
- Process optimization
- Predictive maintenance

The ability of DNNs to process large datasets makes them particularly suitable for Industry 4.0 pharmaceutical manufacturing environments (44).

9.6 Ensemble Learning Approaches

Ensemble learning combines multiple machine learning models to improve prediction accuracy and robustness. Common ensemble methods include Random Forest, Gradient Boosting, XGBoost, and AdaBoost (45).

Advantages include:

- Improved predictive performance
- Reduced model bias
- Enhanced robustness
- Better generalization capability

Ensemble methods have been successfully employed for formulation optimization, dissolution prediction, and stability assessment of oral solid dosage forms (45).

Table 11. Common Machine Learning Models in Pharmaceutical Development

Model	Type	Major Applications
Artificial Neural Network	Supervised	Dissolution and stability prediction
Random Forest	Ensemble	Variable selection and optimization
Support Vector Machine	Supervised	Classification and regression
Decision Tree	Supervised	Risk assessment
Deep Neural Network	Deep Learning	Complex predictive modeling
XGBoost	Ensemble	Formulation optimization

10. Recent Advances and Case Studies

The rapid advancement of artificial intelligence and machine learning technologies has led to numerous successful applications in pharmaceutical development. Recent studies have demonstrated the potential of AI to optimize formulations, predict critical quality attributes, improve manufacturing efficiency, and accelerate product development timelines (46).

The increasing availability of pharmaceutical big data, cloud computing platforms, and advanced analytical tools has further expanded the scope of AI applications in oral solid dosage form development. Several pharmaceutical companies have integrated AI-driven platforms into formulation development and manufacturing workflows to enhance productivity and reduce costs (47).

10.1 AI-Based Formulation Optimization

Researchers have successfully applied machine learning models to optimize tablet formulations by predicting the influence of formulation variables on dissolution behavior, hardness, friability, and disintegration time. Studies have reported significant reductions in the number of experimental trials required for formulation optimization compared with traditional approaches (48).

Case Study 1: Immediate Release Tablet Optimization

A machine learning-based optimization model was developed to predict tablet hardness and dissolution characteristics using formulation composition and processing parameters. The model accurately identified optimal excipient concentrations and reduced development time by approximately 40% (48).

10.2 AI in Dissolution Prediction

Dissolution testing is a critical quality assessment tool for oral solid dosage forms. Deep learning and neural network models have demonstrated high accuracy in predicting dissolution profiles using formulation and process variables as input parameters (49).

Case Study 2: Dissolution Modeling

Researchers developed an ANN-based model capable of predicting dissolution profiles for sustained-release tablets with prediction accuracies exceeding 90%. The model minimized the need for extensive laboratory testing and accelerated formulation development (49).

10.3 AI-Assisted Manufacturing Optimization

AI-enabled predictive analytics and real-time monitoring systems have been increasingly employed in pharmaceutical manufacturing. These systems continuously analyze process data and optimize manufacturing conditions to ensure product quality and process efficiency (50).

Case Study 3: Continuous Manufacturing

A pharmaceutical manufacturing facility implemented machine learning algorithms for real-time process monitoring during tablet production. The system reduced process variability, improved batch consistency, and decreased production downtime by enabling proactive process adjustments (50).

10.4 AI in Pharmaceutical Quality Control

Computer vision systems integrated with deep learning algorithms are increasingly used for automated inspection of tablets and capsules. These systems can detect defects such as cracks, chips, discoloration, and coating irregularities with high accuracy (51).

Case Study 4: Automated Tablet Inspection

A deep learning-based image analysis platform was employed for tablet defect detection. The system achieved defect classification accuracy greater than 95% and significantly reduced manual inspection requirements (51).

Table 12. Recent AI Applications in Pharmaceutical Development

Application Area	AI Technique	Outcome
Formulation Optimization	ANN	Reduced experimental trials
Dissolution Prediction	Deep Learning	Improved prediction accuracy
Manufacturing Control	Machine Learning	Enhanced process efficiency
Quality Control	Computer Vision	Automated defect detection
Stability Prediction	Random Forest	Faster shelf-life estimation

11. Benefits of AI in Oral Solid Dosage Form (OSDF) Development

Artificial Intelligence (AI) has significantly transformed oral solid dosage form development

by enabling data-driven decision-making, predictive modeling, and process automation. The application of AI technologies throughout the pharmaceutical product lifecycle improves formulation efficiency, product quality, and manufacturing productivity. AI-based systems can rapidly analyze large datasets, identify hidden relationships among variables, and predict outcomes with greater accuracy than conventional statistical approaches (52).

One of the major advantages of AI is the reduction in product development time. Traditional formulation development often requires extensive experimental trials and iterative optimization studies. AI models can predict optimal formulation compositions and process parameters, thereby minimizing the number of laboratory experiments required (53).

AI also enhances product quality by enabling precise control of critical process parameters and critical quality attributes. Predictive algorithms support Quality by Design (QbD) implementation and facilitate the development of robust formulations with consistent performance (54).

Furthermore, AI contributes to cost reduction through decreased material consumption, reduced batch failures, improved resource utilization, and accelerated regulatory submissions. Real-time monitoring systems and predictive maintenance strategies also improve manufacturing efficiency and equipment reliability (55).

Table 13. Benefits of AI in Oral Solid Dosage Form Development

Benefit	Impact
Faster Development	Reduced experimental workload
Cost Reduction	Lower material and labor costs
Predictive Modeling	Improved formulation success rate
Process Optimization	Enhanced manufacturing efficiency
Quality Control	Better product consistency
Risk Management	Early detection of process deviations
Regulatory Support	Improved documentation and compliance

12. Challenges and Limitations

Despite its numerous advantages, the implementation of AI in pharmaceutical development faces several challenges. One of the most significant limitations is the availability of high-quality datasets. Machine learning models require large, accurate, and representative datasets for training and validation. In many pharmaceutical applications, data may be limited, fragmented, or inconsistent, reducing model performance and reliability (56).

Another challenge is model interpretability. Complex AI models, particularly deep learning algorithms, often function as "black boxes," making it difficult to understand how predictions are generated. This lack of transparency may hinder regulatory acceptance and limit practical implementation in highly regulated pharmaceutical environments (57).

The integration of AI technologies into existing pharmaceutical manufacturing systems also requires substantial investment in infrastructure, software, computational resources, and workforce training. Small and medium-sized pharmaceutical companies may face financial and technical barriers to adoption (58).

Regulatory uncertainty remains another important challenge. Although regulatory agencies recognize

the potential of AI, comprehensive guidelines for validation, implementation, and lifecycle management of AI-based systems are still evolving (59).

Key Challenges of AI in Pharmaceutical Development

- Limited availability of high-quality datasets
- Data privacy and security concerns
- Model interpretability issues
- High implementation costs
- Lack of skilled personnel
- Regulatory uncertainties
- Integration with legacy systems
- Model validation and maintenance requirements

13. FUTURE PERSPECTIVES

The future of AI in oral solid dosage form development is highly promising. Advances in machine learning, deep learning, cloud computing, big data analytics, and digital technologies are expected to further accelerate pharmaceutical innovation. AI is anticipated to become an integral component of next-generation pharmaceutical manufacturing and formulation development strategies (60).

One of the most promising developments is the concept of digital twins, which are virtual replicas of pharmaceutical products and manufacturing processes. Digital twin technology combined with AI can simulate formulation behavior, predict process outcomes, and optimize manufacturing operations without extensive physical experimentation (61).

Autonomous formulation development represents another emerging area. AI-driven systems may eventually design, optimize, and validate formulations with minimal human intervention, significantly reducing development timelines and resource requirements (62).

The integration of AI with Industry 4.0 technologies, Internet of Things (IoT) devices, robotics, and advanced Process Analytical Technology (PAT) tools is expected to facilitate fully connected and intelligent pharmaceutical manufacturing systems (63).

AI is also likely to play a major role in personalized medicine by enabling patient-specific dosage form design based on genetic, physiological, and clinical data. Such advancements could improve therapeutic outcomes and patient adherence (64).

Table 14:Future Applications of AI in OSDF Development

Emerging Technology	Potential Application
Digital Twins	Virtual process simulation
Deep Learning	Advanced predictive modeling
IoT Integration	Real-time process monitoring
Robotics	Automated manufacturing
Cloud Computing	Large-scale data analytics
Personalized Medicine	Patient-specific formulations

CONCLUSION

Artificial Intelligence has emerged as a transformative technology in pharmaceutical research and development, offering innovative solutions for the development and optimization of oral solid dosage forms. The integration of AI techniques, including machine learning and deep

learning, has enabled a shift from conventional trial-and-error approaches to data-driven formulation and manufacturing strategies. AI facilitates efficient analysis of complex pharmaceutical datasets, enabling accurate prediction of formulation performance, optimization of process parameters, and enhancement of product quality.

In oral solid dosage form development, AI has demonstrated significant potential in preformulation studies, formulation design, excipient selection, dissolution prediction, stability assessment, manufacturing optimization, and quality control. The implementation of AI-driven models has contributed to reduced development timelines, lower costs, improved process understanding, and enhanced regulatory compliance. Furthermore, the integration of AI with Quality by Design principles supports the development of robust pharmaceutical products with consistent quality and performance.

Despite challenges related to data quality, model interpretability, infrastructure requirements, and regulatory considerations, continuous advancements in computational technologies and data analytics are expected to accelerate the adoption of AI across the pharmaceutical industry. Emerging innovations such as digital twins, autonomous formulation systems, smart manufacturing, and personalized medicine are likely to further expand the scope of AI applications in pharmaceutical sciences.

Overall, Artificial Intelligence represents a powerful tool for modernizing oral solid dosage form development and manufacturing. Its ability to improve efficiency, accuracy, and decision-making positions AI as a key enabler of future pharmaceutical innovation, supporting the development of safer, more effective, and high-quality drug products for patients worldwide.

REFERENCES

1. Russell SJ, Norvig P. Artificial Intelligence: A Modern Approach. 4th ed. London: Pearson; 2021.
2. Goodfellow I, Bengio Y, Courville A. Deep Learning. Cambridge: MIT Press; 2016.
3. Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, et al. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019;18(5):435–441.
4. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80–93.
5. Kankala RK, Wang SB, Chen AZ. Machine learning in pharmaceutical formulation development. Adv Drug Deliv Rev. 2022;188:114450.
6. Lohith K, Venkatesh MP, Kumar TM. Applications of artificial intelligence in pharmaceutical technology. J Pharm Innov. 2021;16(4):817–829.
7. Patel L, Shukla T, Huang X, Ussery DW, Wang S. Machine learning methods in pharmaceutical product development. Pharmaceutics. 2023;15(2):423.
8. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436–444.
9. Altae-Tran H, Ramsundar B, Pappu AS, Pande V. Low data drug discovery with deep learning. ACS Cent Sci. 2017;3(4):283–293.
10. Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. Drug Discov Today. 2019;24(3):773–780.
11. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–477.

12. Aulton ME, Taylor KMG. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 6th ed. London: Elsevier; 2022.
13. Allen LV, Ansel HC. Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. 12th ed. Philadelphia: Wolters Kluwer; 2022.
14. Agrawal H, Kaul G. Artificial intelligence in pharmaceutical product development and manufacturing. Pharm Technol. 2021;45(5):18–27.
15. Kankala RK, Xu XM, Liu CG, Chen AZ. Machine learning in pharmaceutical product development and process optimization. Int J Pharm. 2023;635:122755.
16. Shah P, Kendall F, Khozin S, Goosen R, Hu J, Laramie J, et al. Artificial intelligence and machine learning in clinical development and pharmaceutical sciences. Clin Pharmacol Ther. 2019;106(1):164–172.
17. Sinko PJ. Martin's Physical Pharmacy and Pharmaceutical Sciences. 8th ed. Philadelphia: Wolters Kluwer; 2023.
18. Tetko IV, Baskin II, Varnek A. Machine learning approaches for prediction of physicochemical properties in drug development. Drug Discov Today. 2020;25(5):873–884.
19. Peeters J, Bouckaert F, Vervaet C. Machine learning-assisted formulation optimization in pharmaceutical manufacturing. Int J Pharm. 2021;607:120962.
20. Han R, Yang Y, Wang X. Artificial neural network modeling for pharmaceutical formulation optimization. Pharmaceutics. 2022;14(3):615.
21. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 9th ed. London: Pharmaceutical Press; 2020.
22. Zhang Z, Wu H, Wang Y, Liu J. Machine learning approaches for pharmaceutical formulation development and optimization. Pharmaceutics. 2022;14(11):2403.
23. Qiu Y, Zhang GGZ, Liu L. Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice. 3rd ed. London: Academic Press; 2023.
24. Leane M, Pitt K, Reynolds G. Machine learning and dissolution prediction in oral solid dosage forms. Eur J Pharm Biopharm. 2021;164:75–87.
25. Waterman KC, Adami RC. Accelerated stability assessment using predictive modeling approaches. J Pharm Sci. 2020;109(6):1890–1900.
26. Fonteyne M, Vercruysse J, De Leersnyder F, Van Snick B, Vervaet C, Remon JP, Beer TD. Process analytical technology for continuous manufacturing of solid-dosage forms. Trends Anal Chem. 2015;67:159–166.
27. Lee J, Davari H, Singh J, Pandhare V. Industrial Artificial Intelligence for Industry 4.0-based manufacturing systems. Manuf Lett. 2018;18:20–23.
28. Iveson SM, Litster JD, Hapgood K, Ennis BJ. Nucleation, growth and breakage phenomena in agitated wet granulation processes. Powder Technol. 2001;117(1–2):3–39.
29. Wu H, White M, Khan M. Machine learning approaches for wet granulation process optimization in pharmaceutical manufacturing. Int J Pharm. 2022;617:121603.
30. Alderborn G. Tablets and compaction. In: Aulton ME, editor. Aulton's Pharmaceutics. 6th ed. London: Elsevier; 2022. p. 505–540.
31. Ibrić S, Djuriš J, Parojčić J, Djurić Z. Artificial neural networks in pharmaceutical product development and manufacturing. Adv Drug Deliv Rev. 2012;64(9):940–953.
32. Felton LA. Film coating of oral solid dosage forms. In: Qiu Y, Zhang GGZ, Liu L, Porter W, editors. Developing Solid Oral Dosage Forms. 3rd ed. London: Academic Press; 2023. p. 563–589.

33. Pereira G, Sousa J, Pinto JF. Artificial intelligence and computer vision for coating process monitoring in pharmaceutical manufacturing. Pharmaceutics. 2023;15(4):1089.
34. Yu LX. Pharmaceutical quality by design: Product and process development, understanding, and control. Pharm Res. 2008;25(4):781–791.
35. Rathore AS, Winkle H. Quality by Design for pharmaceuticals: Regulatory perspective and implementation. PDA J Pharm Sci Technol. 2009;63(4):301–315.
36. Reklaitis GV. Process monitoring and quality control in pharmaceutical manufacturing using machine learning. Comput Chem Eng. 2021;149:107308.
37. Nayar P, Purohit H, Ghosh A. Deep learning-based defect detection and quality assessment of pharmaceutical tablets. J Pharm Innov. 2024;19(1):45–58.
38. Zhang L, Zhang J, Wang Y. Machine learning applications in pharmaceutical research and development. Drug Discov Today. 2021;26(12):2841–2851.
39. Winkler DA. The role of machine learning in pharmaceutical product development. Future Med Chem. 2020;12(18):1685–1697.
40. Agatonovic-Kustrin S, Beresford R. Basic concepts of artificial neural network modeling and its application in pharmaceutical research. J Pharm Biomed Anal. 2000;22(5):717–727.
41. Svetnik V, Liaw A, Tong C, Culberson JC, Sheridan RP, Feuston BP. Random Forest: A classification and regression tool for compound classification and QSAR modeling. J Chem Inf Comput Sci. 2003;43(6):1947–1958.
42. Cortes C, Vapnik V. Support-vector networks. Mach Learn. 1995;20(3):273–297.
43. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. Boca Raton: CRC Press; 2017.
44. Schmidhuber J. Deep learning in neural networks: An overview. Neural Netw. 2015;61:85–117.
45. Chen T, Guestrin C. XGBoost: A scalable tree boosting system. Proceedings of the 22nd ACM SIGKDD Conference on Knowledge Discovery and Data Mining. 2016:785–794.
46. Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of artificial intelligence for computer-assisted drug discovery. Chem Rev. 2019;119(18):10520–10594.
47. Bannigan P, Aldeghi M. Machine learning in pharmaceutical development and manufacturing. Nat Rev Drug Discov. 2023;22(9):701–719.
48. García-Muñoz S, Morales J, López F. Machine learning-assisted optimization of tablet formulations. Pharmaceutics. 2022;14(9):1886.
49. Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, et al. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 2019;47(D1):D930-D940.
50. Kourti T, Davis B. Advanced process monitoring and control in pharmaceutical manufacturing using machine learning. Comput Chem Eng. 2022;162:107780.
51. Pathak KA, Kafle P, Vikram A. Deep learning-based defect detection in film-coated tablets using a convolutional neural network. Int J Pharm. 2025;671:125220. Doi:10.1016/j.ijpharm.2025.125220
52. Korotcov A, Tkachenko V, Russo DP, Ekins S. Comparison of deep learning with multiple machine learning methods and metrics using diverse drug discovery datasets. Mol Pharm. 2017;14(12):4462–4475.
53. Bukhari NI, Alshammari TM, Alharbi KS. Artificial intelligence-driven formulation

development in pharmaceutical sciences. Pharmaceutics. 2023;15(6):1625.
54. Ferreira AP, Tobyn MJ. Application of artificial intelligence to quality-by-design and pharmaceutical development. Int J Pharm. 2021;603:120697.
55. Bhalode P, Ierapetritou M. Artificial intelligence and process optimization in pharmaceutical manufacturing. Comput Chem Eng. 2022;164:107879.
56. Pesapane F, Codari M, Sardanelli F. Artificial intelligence in medicine: Challenges and opportunities. Br J Radiol. 2018;91(1085):20170595.
57. Samek W, Wiegand T, Müller KR. Explainable artificial intelligence: Understanding, visualizing and interpreting deep learning models. ITU J ICT Discov. 2017;1(1):39–48.
58. Javaid M, Haleem A, Singh RP, Suman R. Industry 4.0 technologies and barriers to implementation in pharmaceutical manufacturing. J Ind Inf Integr. 2022;25:100261.
59. Muehlematter UJ, Daniore P, Vokinger KN. Approval of artificial intelligence and machine learning-based medical technologies by regulatory agencies. Lancet Digit Health. 2021;3(4):e195–e203.
60. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in pharmaceutical product development and manufacturing: Future perspectives. Drug Discov Today. 2023;28(7):103638.
61. Bruynseels K, Santoni de Sio F, van den Hoven J. Digital twins in healthcare and pharmaceutical sciences. Front Digit Health. 2021;3:650503.
62. Häse F, Roch LM, Aspuru-Guzik A. Next-generation experimentation with self-driving laboratories and autonomous formulation development. Trends Chem. 2019;1(3):282–291.
63. Xu X, Lu Y, Vogel-Heuser B, Wang L. Industry 4.0 and smart manufacturing technologies: A review. Int J Prod Res. 2021;59(10):2941–2962.
64. He H, Xu M, Zhou R. Artificial intelligence-enabled personalized medicine and future pharmaceutical development. Adv Drug Deliv Rev. 2023;198:114909.

HOW TO CITE: Priti Shinde, S. Ambore, Artificial Intelligence in Oral Solid Dosage Form Development and Optimization, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 7, 1124-1144, https://doi.org/10.5281/zenodo.21217922